Efficacy of Stiripentol and the Clinical Outcome in Dravet Syndrome

J Child Neurol. 2019 Jan;34(1):33-37. doi: 10.1177/0883073818811538. Epub 2018 Oct 26.

Abstract

Dravet syndrome is a rare and progressive epileptic encephalopathy of infancy. Stiripentol reduces the seizure frequency in patients with Dravet syndrome. We evaluated the clinical characteristics of patients with Dravet syndrome and their response to stiripentol. We retrospectively collected the data of 21 patients (11 females; mean age, 8.2 years, range: 5.4-15 years) with Dravet syndrome who were treated with stiripentol in our outpatient clinic between June 2016 and June 2017. Patients with seizure reduction ≥50% were considered responders. Most of our patients had severe (47%) or moderate (33%) cognitive disabilities, although 14% had mild cognitive disability. There was a significant difference in both status epilepticus and age between the groups with normal/mild versus severe/moderate neurocognitive prognoses. Of the patients, 85.7% were using stiripentol. The mean duration of stiripentol use was 41.2 months (range: 24-64 months). In 12 patients (57%), the seizure frequency decreased by more than 50%, and 2 of them were seizure-free. Status epilepticus was not recorded after stiripentol treatment in 8 of 11 patients with status epilepticus. Despite the small sample size, our results suggest that stiripentol has a favorable efficacy. In addition, considering the absence of status epilepticus after treatment and the negative effects of status epilepticus on cognitive development, early treatment should be initiated in SD patients, for whom disease control is difficult.

Keywords: Dravet; refractor epilepsy; stiripentol.

MeSH terms

  • Adolescent
  • Anticonvulsants / therapeutic use*
  • Child
  • Child, Preschool
  • Cognitive Dysfunction / complications
  • Dioxolanes / therapeutic use*
  • Drug Resistant Epilepsy / complications
  • Drug Resistant Epilepsy / drug therapy
  • Epilepsies, Myoclonic / complications
  • Epilepsies, Myoclonic / drug therapy*
  • Female
  • Humans
  • Male
  • Retrospective Studies
  • Seizures / complications
  • Seizures / drug therapy
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Dioxolanes
  • stiripentol